ERBB2
31 abstracts
Abstract
Differences in genomic and transcriptomic landscapes of human papillomavirus (HPV)–positive neuroendocrine neoplasms and HPV-positive carcinoma.Org: Loma Linda University Health| School of Medicine, Wayne State University/Karmanos Cancer Center, Division of Hematology/Oncology, University of California, Division of Gynecologic Oncology, Department of Oncology, Karmanos Cancer Institute, Division of Gynecologic Oncology, The University of Cincinnati Cancer,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.Org: Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Chris O'Brien Lifehouse, Royal North Shore Hospital, Sydney, Australia, Westmead Cancer Care Centre,
Abstract
Korean Precision Medicine Networking Group study of molecular profiling guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) II (KCSG AL 22-09).Org: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, Seoul National University Hospital, Jongno-Gu, South Korea, Korea University Anam Hospital, Seoul, South Korea, Samsung Medical Center, Seoul, South Korea,
Abstract
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.Org: NeoGenomics Ltd, Cambridge, United Kingdom, Medipole Lyon Villeurbanne, Villeurbanne, France, Infirmerie Protestante, Caluire Et Cuire, France, Institut de Cancérologie Strasbourg Europe ICANS, Strasbourg, France,
Abstract
Caveat emptor: A descriptive analysis of guideline-recommended biomarker inclusion in targeted NGS panels for metastatic non-small cell lung cancer (mNSCLC).Org: Illumina, Inc.,
Abstract
Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?Org: BC Cancer Agency Vancouver Island Centre, Guardant Health Inc., Duke University Medical Center, Guardant Health, Inc., The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Progress report of a cross-organ and biomarker-based platform study: BELIEVE trial NCCH1901.Org: National Cancer Center Hospital East, Kashiwa, Japan, Chuo-Ku, Japan, Department of Laboratory Medicine and Pathology, University of Washington, Tokyo, Japan, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Survival associations and driver oncogene overlap for copy-number amplifications of ERBB2, KRAS and MET in non-small cell lung cancer.Org: Tom Baker Cancer Center, Calgary, AB, Canada, Caris Life Sciences, Irving, TX, Irving, TX, Phoenix, AZ,
Abstract
Gene expression profiling of paired primary breast cancers and brain metastases to identify brain metastases-specific biological changes.Org: University of Padua School of Medicine, Division of Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Montefiore Medical Center, Albert Einstein College of Medicine, UOSD Hereditary Tumors, Veneto Institute of Oncology IOV-IRCCS, CHU Montpellier,
Abstract
Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?Org: Weill Cornell Medicine - Qatar, Doha, Qatar, Qatar, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC,
Abstract
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Department of Molecular Pharmacology and Therapeutics,
Abstract
Methylated ctDNA as a biomarker for detecting previously undetectable clinically significant somatic mutations.Org: BillionToOne, Inc., UC San Diego Moores Cancer Center,
Abstract
Comprehensive genomic profiling of Taiwanese patients with breast cancer using a novel targeted panel: Preliminary analyses from a prospective triple-negative cohort.Org: Taipei Veterans General Hospital, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
EGFR/ERBB2 aberrations in Chinese biliary tract carcinomas.Org: Eastern Hepatobiliary Surgery Hospital, Shanghai, China, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China, The Medical Department, Nanjing Simcere Medical Laboratory Science Co., Ltd, Nanjing, China,
Abstract
Analytical performance assessment of ASPYRE-Lung: A new assay for rapid detection of actionable variants from tissue and plasma in NSCLC patients.Org: Biofidelity Ltd,
Abstract
Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort.Org: Fortis Cancer Institute, Sir H N Reliance Foundation Hospital and Research Centre, BALCO Medical Center, Fortis Hospital Mulund, Datar Cancer Genetics,
Abstract
Differences of RAS/BRAF mutations between ISCC and RSCC in a Chinese population.Org: the General Hospital of Southern Theater Command，PLA., Guangzhou, China, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Oncomine Dx Express CE-IVD liquid biopsy assay for non-small cell lung cancer: Performance review and analytical validation.Org: Thermo Fisher Scientific, Austin Health, Txinno Bioscience,
Abstract
Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: The experience of an academic hospital.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Antwerp University Hospital, University Hospital of Antwerp, Multidisciplinary Oncologic Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium,
Abstract
Identification of clinically actionable biomarkers in an Indian cancer cohort using comprehensive genomic profiling (CGP): An institutional experience.Org: Triesta Sciences, HCG Cancer Center Mumbai, Strand Life Sciences,
Abstract
Comprehensive genomic analysis of salivary gland carcinomas in a Chinese population.Org: Department of Oral and Maxillofacial Head & Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai OrigiMed Co., Ltd, Shanghai, China,
Abstract
Copy number variation (CNV) calling of MET, MYC, and ERBB2 using PiVAT bioinformatic platform.Org: Shanghai Zhengu Biological Technology Co., Ltd, Pillar Biosciences Inc.,
Abstract
The mutational landscape of circulating cell free DNA in patients with gastric cancer.Org: The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Oncology,Daqing Oilfield Hospotal, Harbin, China, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, HaploX Biotechnology, Shenzhen, China, China-Japan Union Hospital of Jilin University, Jilin, China,
Abstract
Analysis of cell-free DNA (cfDNA) fragmentomes and prediction scores across distinct molecular subtypes.Org: Delfi Diagnostics, Inc., DELFI Diagnostics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Johns Hopkins University School of Medicine, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Does the landscape of comprehensive genomic profiling in patients with advanced stage lung cancer in India differ from data from the western countries.Org: Fortis Cancer Institute, New Delhi, India, Fortis Cancer Institute, Bangalore Karnataka, India, Fortis Cancer Institute, Gurgaon, Haryana, India, Fortis Cancer Institute, Delhi, India, Fortis Hospital and research centre, New Delhi, India,
Abstract
Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection.Org: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jichenjunchuang Medical Laboratory(Hangzhou), Co. Ltd., Hangzhou, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Comparative analysis of the mutation detection using malignant pleural effusion and blood cell-free DNA samples in lung cancer.Org: Department of Thoracic Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China, Department of Oncology,The Fourth Hospotal of Heilongjiang Province, Harbin, China, Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hunan, China., Thoracic surgery，Affiliated hospital of Guizhou Medical University, Guiyang, China,
Abstract
Real world genomics in metastatic urothelial carcinoma (mUC).Org: University Hospitals Seidman Cancer Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Department of Medical Genetics, Cleveland, OH, Cancer Informatics,
Abstract
Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.Org: University of Modena and Reggio Emilia, Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori (IRST), Molecular Pathology Laboratory, Program Clinical and Experimental Medicine,